Акции Zoetis упали на 39,5% с начала года, несмотря на превышение прогнозов по прибыли во втором квартале

Акции крупнейшей в мире компании по здоровью животных Zoetis обвалились на 39,5% с начала года, значительно отстав от роста рынка. Несмотря на то, что отчетность за второй квартал показала прибыль выше ожиданий аналитиков, выручка компании оказалась ниже прогнозов.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

Zoetis Inc. (ZTS) is the world's leading animal health company, developing, manufacturing, and commercializing vaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock. The Parsippany, New Jersey-based company's products help veterinarians, livestock producers, and pet owners predict, prevent, detect, and treat diseases. It has a market capitalization of $31.9 billion. Companies worth $10 billion to $200 billion are generally described as "large-cap stocks," and Zoetis definitely fits that description, with its market cap exceeding this threshold, reflecting its substantial size, influence, and dominance within the Specialty and Generic Drug Manufacturers industry. Zoetis is the largest animal health company by revenue, supported by strong brand loyalty and a diverse product portfolio. Its global presence across 100+ countries, extensive patent portfolio, and strong R&D capabilities support innovation, product development, and long-term growth. More News from Barchart - Nvidia CEO Jensen Huang Says His $3.5 Billion MediaTek Deal Is 'Not Circular' Because 'They Do Their Own Business' - Strategy's Strategy Appears to Have Failed, and the Outlook of MSTR Stock Is Unfavorable - A Potential SpaceX Deal Could Meaningfully Accelerate Growth for Technip Stock - Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Despite its notable strengths, ZTS is currently 50.9% below its 52-week high of $155.15, reached on September 5, 2025. The stock has also declined marginally over the past three months, trailing the S&P 500 ($SPX), which has risen marginally during the same period. Shares of ZTS have plunged 39.5% year-to-date and 50.2% over the past 52 weeks, significantly underperforming the S&P 500's 12% YTD gain and 19.5% return over the past year. While ZTS has been trading below its 200-day moving average for the past year, it recently climbed above the 50-day moving average in mid-August. Zoetis has lagged the broader market as its 2.7% annual revenue growth over the past two years has trailed healthcare peers, while projected sales declines point to a challenging demand environment. Stagnant returns on capital also suggest limited improvement in the company's business quality. However, on August 6, Zoetis shares moved up 3.9% after reporting its Q2 results. Its adjusted EPS of $1.87 surpassed Wall Street expectations of $1.86, while the company's revenue of $2.50 billion missed Wall Street forecasts of $2.51 billion.